The 6 analysts offering 1 year price forecasts for LCTX have a max estimate of — and a min estimate of —.
Analyst rating
Based on 7 analysts giving stock ratings to LCTX in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
LCTX EPS for the last quarter is −0.07 ILA despite the estimation of −0.15 ILA. In the next quarter EPS is expected to reach −0.13 ILA. Track more of LINEAGE THERAP financials and stay on top of what is up with the company.
In the next quarter LINEAGE THERAP revenue is expected to reach 5.22 M ILA. Check out LINEAGE THERAP revenue and earnings and make informed decisions.
According to analysts, LCTX price target is 1,562.36 ILA with a max estimate of 1,874.84 ILA and a min estimate of 749.93 ILA. Check if this forecast comes true in a year, meanwhile watch LINEAGE THERAP stock price chart and keep track of the current situation with LCTX news and stock market news.
We've gathered opinions of 7 analysts rating LCTX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.